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Abstract
Background: Foot problems are common in people with gout yet the prevalence of current foot problems in
people with gout and the burden they present to healthcare systems is not known. This cross-sectional study
aimed to determine the prevalence and associations of hallux valgus, foot pain and disability in people with gout,
and to assess the frequency with which foot problems lead to consultation with healthcare professionals.
Methods: Adults registered with 20 general practices who had consulted their GP about gout or been prescribed
allopurinol or colchicine in the preceding two years were mailed a questionnaire. Prevalence of hallux valgus, foot
pain in the last month, and disabling foot pain in the mailed population were ascertained using validated
instruments and estimated by inverse-weighted logistic regression. Associations with socio-demographic, comorbid
and gout-specific factors were examined using logistic regression. Participants were asked if they had seen health
care professionals for foot problems within the preceding 12 months.
Results: One thousand one hundred eighty-four questionnaires were received (response 66 %). Prevalence of hallux
valgus was 36.3 %, foot pain in the last month 22.3 % and disabling foot pain 14.5 %. Hallux valgus associated with
age (adjusted OR 1.47 per 10-year increase, 95 % CI 1.26, 1.72) and female gender (2.03; 1.31, 3.15). Foot pain in the
last month associated with age (1.24; 1.00, 1.55), obesity (BMI 30.0–34.9 2.67; 1.32, 5.38; BMI ≥ 35.0 3.16; 1.44, 6.93),
mild depression (2.04; 1.09, 3.81) and polyarticular gout attacks (1.86; 1.18, 2.95). Disabling foot pain associated with
age (1.42; 1.08, 1.87), obesity (BMI 30.0–34.9 3.73; 1.54, 9.09; BMI ≥ 35.0 4.36; 1.64, 11.64), depression (mild 2.63; 1.25,
5.53; moderate 3.53; 1.11, 11.26) and ischaemic heart disease (2.45; 1.32, 4.53). In the previous 12 months, 495
(42.8 %) reported consulting their GP about their feet and 281 (23.7 %) a podiatrist/chiropodist.
Conclusions: Foot problems are common in people with gout and frequently lead to healthcare consultation.
Hallux valgus has similar associations to those seen in the general population, whereas foot pain associates with
obesity and gout characteristics, and disabling foot pain with obesity and comorbidity. Patient assessment should
consider foot problems and offer specific treatment where relevant.
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Background
Gout is the most prevalent inflammatory arthropathy
and affects 2.5 % of adults in the UK [1]. It shows a
striking tendency to affect the joints of the foot and
ankle complex with involvement of the 1st metatarso-
phalangeal joint (MTPJ) being the clinical hallmark of
gout. As many as 89 % of patients experience involvement
of the 1st MTPJ at some point in the disease course, with
56–78 % of first attacks affecting this joint [2]. The mid-
foot joints and ankle are the next most frequent sites of
acute attacks. However, whilst acute attacks of excruciat-
ing joint pain and swelling are characteristic of crystal
synovitis, gout also has well-recognised chronic manifesta-
tions including an erosive, destructive arthropathy and a
pathogenetic link with osteoarthritis (OA) [3]. Both hallux
valgus deformity and chronic big toe pain are more com-
mon in people with gout than in age- and gender-
matched control subjects [4]. A recent small hospital-
based study found that people with chronic gout have
greater levels of general and foot-specific disability, pain
and impairment, slower walking velocity, reduced step
and stride length, reduced peak plantar pressure under the
hallux, and higher mid-foot pressure-time integrals [5].
Although chronic foot problems appear to be more
common in people with gout than in people of a similar
age and gender without gout, the reasons why people
with gout experience these problems are less clear. Age,
gender, obesity, footwear, foot posture, joint pain and
OA have been suggested to be risk factors for hallux val-
gus and foot pain in the general population [6–15]. Foot-
wear worn by people with gout frequently provides poor
cushioning, lack of support, lack of stability, and motion
control, and demonstrates excessive wear patterns [16].
However, it is not known whether co-morbid disease,
gout-related characteristics and indicators of gout sever-
ity are risk factors for chronic foot problems in gout.
Whilst it is well-recognised that foot involvement is a
cardinal feature of gout and the vast majority of gout
sufferers experience acute attacks affecting the foot [2],
there are few studies of the prevalence of current foot
problems in people with gout and the frequency with
which these lead to consultation with healthcare profes-
sionals is not known. However, in general population
studies not specific to gout, 12 % of people with foot prob-
lems consulted their GP about them over an 18-month
period and 18 % consulted a podiatrist over 12 months
[17, 18], suggesting that foot problems present a signifi-
cant burden to healthcare systems. Such information is
needed to inform healthcare provision.
The objectives of this study were (i) to determine the
prevalence of hallux valgus, foot pain and disabling foot
pain amongst people with gout, (ii) to describe the ana-
tomical location of foot pain, (iii) to investigate which
demographic, lifestyle, psychological, co-morbid and gout-
related factors are associated cross-sectionally with foot
problems in gout, and (iv) to describe the 12-month preva-
lence of consultation with a general practitioner, physio-
therapist or podiatrist/chiropodist for foot problems.
Methods
Study design
This paper uses baseline data from a 3-year primary
care-based prospective observational cohort study [19].
Ethical approval was obtained from North West - Liver-
pool East Research Ethics Committee (REC reference
number: 12/NW/0297).
Study population
Gout patients aged 18 years and older were recruited
from 20 general practices across the West Midlands,
UK. Electronic primary care records in the participating
practices were searched over the preceding two years to
identify patients with a Read code for a consultation for
gout or a prescription of allopurinol or colchicine. Read
codes are a coded hierarchy of clinical codes, based on
ICD-9 codes, and are widely used in primary care in the
UK.
Data collection
Eligible patients were mailed a self-complete question-
naire that requested information about aspects of gout,
foot problems and general health. Specific questions
about gout included age at gout diagnosis, whether an
attack of gout was being experienced at the time of
questionnaire completion, number of attacks experi-
enced in the preceding 12 months, history of gout
attacks affecting more than one joint (oligo/polyarticular
gout) and current use of allopurinol. A validated line-
drawing instrument was used to assess self-reported
hallux valgus [20]. This instrument consists of five
drawings for each foot, depicting a sequential increase in
the hallux valgus angle of 15° and includes instructions for
participants to compare the line drawings to their own
bare feet while standing and to select the picture that best
represents their left and right feet in turn. Participants were
asked about the presence of pain, aching or stiffness in the
feet in the past month, categorised as occurring on no
days, a few days, some days, most days or all days. The
questionnaire also asked about consultation with their
general practitioner and other health care professionals for
foot problems within the preceding 12 months, and to
indicate the location of foot pain experienced in the right
and left feet in the past month by shading on a foot
manikin (© The University of Manchester 2000. All rights
reserved) [21]. Further validated questionnaires in-
cluded the Manchester Foot Pain and Disability Index
(MFPDI) [22], Generalized Anxiety Disorder Assessment
(GAD7) [23], and Patient Health Questionnaire (PHQ9)
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[24]. Socioeconomic characteristics included marital status,
higher education, current employment status, and ethni-
city. The questionnaire also asked about self-reported
height and weight, comorbidities (diabetes mellitus, hyper-
tension, hyperlipidaemia, myocardial infarction, angina,
stroke and transient ischaemic attack), and alcohol
consumption.
Non-responders to the questionnaire were sent a re-
minder postcard after two weeks. Those who did not re-
spond to the reminder postcard were sent a repeat
questionnaire four weeks after the initial mailing. Partici-
pants were asked to consent to review of their medical
records by the research team. The presence of tophi and
serum uric acid (SUA) levels (highest level recorded)
were ascertained from medical records of consenting
participants over the preceding two years.
Case definitions
Hallux valgus was dichotomised as present or absent for
each foot by classifying the three most severe grades as
present and the two least severe grades as absent [20].
Foot pain was defined as reporting any pain, aching or
stiffness in the feet on most or all days in the past
month [9]. Foot pain location for each foot was deter-
mined from the foot manikin by using a transparent
overlay and classified as 1st MTPJ, hallux, lesser toes,
mid-foot, ankle, plantar heel or posterior heel, as de-
scribed previously [25]. Disabling foot pain was defined
as reporting foot pain in the last month (as defined
above) and reporting at least one of the ten items of the
MFPDI function construct as occurring on most or
every day(s) [26].
Statistical analysis
In order to assess selective non-participation, we compared
the age, gender and neighbourhood deprivation levels of
the mailed sample, responders and non-responders using
simple descriptive statistics. Neighbourhood deprivation
was determined from the rank of the Indices of Multiple
Deprivation (IMD) derived from the individual’s postal
code, and split into tertiles for analysis [27].
Demographic, lifestyle, psychological, co-morbid and
gout characteristics of survey responders were described
using simple descriptive statistics. Body mass index
(BMI) was calculated from self-reported height and
weight. Anxiety was assessed using the GAD7 and cate-
gorised as none (score 0 to 4), mild (5 to 9), moderate
(10 to 14) or severe (15 to 21) [23]. Depression was
assessed using the PHQ9 and categorised as none (score
0 to 4), mild (5 to 9), moderate (10 to 14), moderately
severe (15 to 19) and severe (20 to 27) [24]. Gout dur-
ation was calculated from reported age at first diagnosis.
Prevalence estimates for hallux valgus (unilateral and
bilateral), foot pain in the last month and disabling foot
pain were calculated in (1) survey responders using sim-
ple descriptive statistics and (2) the mailed population
using logistic regression applying inverse probability
weights based on age, gender and decile of deprivation
rank to account for any initial selective non-response to
the survey questionnaire. In those reporting foot pain in
the last month, the percentage reporting pain in the 1st
MTPJ, hallux, lesser toes, mid-foot, ankle, plantar heel
or posterior heel on the foot manikin were calculated.
IMD is a measure of neighbourhood deprivation, mea-
sured at the level of postcode. Therefore individuals
within the sample may have been more similar to others
within the same tertile of IMD score. For this reason, it
was tested, using a variance components model [28],
whether people within tertiles of IMD score were more
similar to each other in terms of their foot pain charac-
teristics (i.e., presence of hallux valgus, foot pain, disab-
ling foot pain) than those in other tertiles. If this
grouping was significant, a multi-level logistic regression
model would be used (grouping individuals within
tertiles), if it was non-significant, a single-level logistic
regression model would be used.
Multi- or single-level logistic regression models were
then applied as appropriate to assess the association of
age, gender, neighbourhood IMD (tertile), BMI (<25,
25.0–29.9, 30.0–34.9, ≥35 kg/m2), anxiety (none, mild,
moderate, severe), depression (none, mild, moderate,
moderately severe, severe), diabetes mellitus, hyperten-
sion, hyperlipidaemia, ischaemic heart disease, cerebro-
vascular disease, gout duration, currently experiencing
gout attack, number of attacks in last 12 months (0,
1–2, ≥3), oligo/polyarticular attacks, and current allo-
purinol use with hallux valgus, foot pain and disabling
foot pain. Results are presented as odds ratios (OR)
with 95 % CIs, unadjusted and then adjusted for the full
range of variables described above.
In order to explore the influence of acute attacks of
gout on ascertainment of foot pain and disabling foot
pain, sensitivity analyses were carried out to determine
the association of demographic and gout-related charac-
teristics with foot pain and disabling foot pain, excluding
those who reported experiencing a gout attack at the
time of completing the questionnaire.
The percentage of respondents who had consulted a
GP, physiotherapist or podiatrist/chiropodist about a
foot problem in the last 12 months was calculated.
Missing data were infrequent, varying from 4 to 7 %
on current gout attack, duration of gout, and BMI to
12 % for depression. Missing values were imputed using
multiple imputation technique and all data then re-
analyzed. Findings did not differ significantly therefore
complete case analyses only are presented.
All analyses were conducted in Stata version 12.1
(Stata Corporation, Texas, USA).
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Results
Study population
The baseline survey population consisted of 1805 people
(Fig. 1), of whom nine were excluded during the mailing
process (died, left the general practice or other serious
health reasons). Of the remaining 1796 people, 1184
(66 %) responded to the baseline survey. Of these, 1079
(91 %) consented to their medical records being reviewed.
Selective non-participation
Responders tended to be older than non-responders,
with a higher proportion aged over 60 years (Table 1).
They were also more likely to be male and live in less
deprived areas.
Characteristics of survey responders
Mean age of responders was 65.6 (SD 12.5) years. Re-
sponders were predominantly male (Table 1), married/
cohabiting, white and had not attended higher education
(Table 2). Just over half were retired. Over 80 % were
overweight or obese (BMI > 25 kg/m2). Self-reported co-
morbidities were common, with hypertension most
prevalent followed by hyperlipidaemia and then diabetes
and vascular disease. Approximately one-quarter re-
ported symptoms of anxiety and depression. Almost half
drank alcohol at least three times per week with 113
(9.7 %) reporting never drinking.
Mean gout duration was 11.9 (SD 12.1) years. Having
at least one attack of gout in the last 12 months was re-
ported by 725 people (64.5 %) and 132 (11.6 %) reported
currently having an attack of gout. Current allopurinol
use was reported by 620 (56.3 %). Of the 1079 people
who consented to medical record review, 25 (2.3 %) had
the presence of tophi recorded in the last two years,
whilst SUA level was recorded in the preceding two
years in 461 (42.7 %) (mean 441 μmol/l, SD 116).
Prevalence of hallux valgus, foot pain and disabling foot
pain
Unilateral hallux valgus, bilateral hallux valgus, foot pain
in the last month and disabling foot pain were reported
by 203 (17.9 %), 215 (19.0 %), 248 (22.1 %) and 155
(14.4 %) responders respectively. On applying the sam-
pling weights, these equate to estimated prevalences in
the mailed sample of 17.7 % (95 % CI 15.6 %, 20.1 %) for
unilateral hallux valgus, 18.6 % (95 % CI 16.4 %, 21.0 %)
for bilateral hallux valgus, 22.3 % (95 % CI 19.9 %,
24.9 %) for foot pain in the last month, and 14.5 % (95 %
CI 12.5 %, 16.8 %) for disabling foot pain.
Of those reporting foot pain in the last month, the 1st
MTPJ was the most common site (72.2 %), followed by
the lesser toes (67.3 %), the midfoot (61.7 %), the hallux
(58.9 %), ankle (54.0 %), posterior heel (35.1 %) and
plantar heel (20.6 %).
Factors associated with hallux valgus, foot pain, and
disabling foot pain
The grouping of people into tertiles of IMD score
accounted for <1.5 % of the overall amount of variation
in hallux valgus, foot pain and disabling foot pain.
Therefore, it was not necessary to take account of this
grouping in analyses and single-level logistic regression
models were used.
Fig. 1 Flowchart showing participant recruitment
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Hallux valgus
In unadjusted analyses, hallux valgus was associated with
age, female gender, mild and moderately- severe depres-
sion, and hypertension (Table 3). On multivariate ana-
lysis, only age (OR 1.47 per 10-year increase in age; 95 %
CI 1.26, 1.72) and female gender (OR 2.03; 95 % CI 1.31,
3.15) remained associated with hallux valgus. There was
no association with other sociodemographic factors, co-
morbidity, obesity, or gout characteristics.
Foot pain
In unadjusted analyses, foot pain was associated with fe-
male gender, being obese/severely obese, anxiety, depres-
sion, diabetes mellitus, ischaemic heart disease, currently
having an attack of gout, the number of gout attacks in the
previous 12 months, and polyarticular attacks (Table 4).
On multivariate analysis, foot pain remained associated
with obesity (obese OR 2.23; 95 % CI 1.16, 4.27; severely
obese OR 2.61; 95 % CI 1.25, 5.45), moderately-severe (OR
3.41; 95 % CI 1.22, 9.57) and severe depression (OR 4.55;
95 % CI 1.20, 17.18), currently experiencing a gout attack
(OR 2.38; 95 % CI 1.35, 4.20), and oligo/polyarticular
attacks (OR 1.67; 95 % CI 1.11, 2.51).
Sensitivity analysis excluding those with a current at-
tack of gout (n = 132) did not alter the findings: age (OR
1.24 per 10-year increase in age; 95 % CI 1.00, 1.55),
obesity (obese OR 2.67; 95 % CI 1.32, 5.38: severely
obese OR 3.16; 95 % CI 1.44, 6.93), mild depression (OR
2.04; 95 % CI 1.09, 3.81) and oligo/polyarticular attacks
(OR 1.86; 95 % CI 1.18, 2.95) were significantly associ-
ated with the presence of foot pain in the last month.
Disabling foot pain
Disabling foot pain was associated with female gender,
obesity, anxiety, depression, diabetes mellitus, hyperlip-
idaemia, ischaemic heart disease, currently having a gout
attack, the number of gout attacks in the previous
12 months, and oligo/polyarticular attacks, on univariate
analysis (Table 5). In adjusted analyses, only obesity
(obese OR 2.44; 95 % CI 1.10, 5.41; severely obese OR
3.10; 95 % CI 1.28, 7.47), depression (moderately severe
OR 4.16; 95 % CI 1.28, 13.51; severe OR 8.81; 95 % CI
2.04, 38.01), ischaemic heart disease (OR 1.84; 95 % CI
1.06, 3.20) and currently having an attack of gout (OR
2.63; 95 % CI 1.39, 4.98) remained significant.
After exclusion of those people reporting a current attack
of gout, age (OR 1.42 per 10-year increase in age; 1.08,
1.87), obesity (obese OR 3.73; 95 % CI 1.54, 9.09: severely
obese OR 4.36; 95 % CI 1.64, 11.64), depression (mild OR
2.63; 95 % CI 1.25, 5.53; moderate OR 3.53; 95 % CI 1.11,
11.26) and ischaemic heart disease (OR 2.45; 95 % CI 1.32,
4.53) were significantly associated with disabling foot pain
in the last month.
Utilisation of health services
495 respondents (42.8 %) reported consulting their GP
in the previous 12 months about their feet, whilst 72
(6.1 %) reported seeing a physiotherapist and 281 (23.7 %)
consulting a podiatrist/chiropodist.
Discussion
In this large primary-care based study of people with
gout, foot problems were prevalent. Over one-third had
unilateral or bilateral hallux valgus and one-fifth had ex-
perienced pain, aching or stiffness in the foot on most
days in the preceding month. Amongst those with foot
pain almost two-thirds reported disabling symptoms.
Hallux valgus was associated with age and female gender
but no association was seen with gout-related or comorbid
Table 1 Age, gender and neighbourhood deprivation differences
between mailed participants, non-responders and responders to
the postal questionnaire. Numbers shown are n (%)
All mailed
participants
Non-responders
and refusals
Responders
N 1805a 612 1184
Gender:
Males 1471 (81.5) 476 (77.8) 990 (83.6)
Females 334 (18.5) 136 (22.2) 194 (16.4)
Age (years):
Under 50 308 (17.1) 164 (26.8) 142 (12.0)
50–59 348 (19.3) 137 (22.4) 210 (17.7)
60–69 480 (26.6) 136 (22.2) 343 (29.0)
70–79 448 (24.8) 107 (17.5) 339 (28.6)
80 and over 221 (12.2) 68 (11.1) 150 (12.7)
Age (years), males:
Under 50 294 (20.0) 155 (32.6) 138 (13.9)
50–59 301 (20.5) 113 (23.7) 187 (18.9)
60–69 401 (27.3) 108 (22.7) 293 (29.6)
70–79 340 (23.1) 65 (13.7) 273 (27.6)
80 and over 135 (9.2) 35 (7.4) 99 (10.0)
Age (years), females:
Under 50 14 (4.2) 9 (6.6) 4 (2.1)
50–59 47 (14.1) 24 (17.7) 23 (11.9)
60–69 79 (23.7) 28 (20.6) 50 (25.8)
70–79 108 (32.4) 42 (30.9) 66 (34.0)
80 and over 86 (25.8) 33 (24.3) 51 (26.3)
Neighbourhood
deprivation (tertiles):
Most deprived 609 (33.8) 237 (38.8) 369 (31.2)
Mid-deprived 595 (33.0) 189 (30.9) 405 (34.2)
Least deprived 600 (33.3) 185 (30.3) 410 (34.6)
aNine of these participants were excluded during the mailing process
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features. Foot pain and related disability both associated
with age, obesity and depression, however foot pain was
associated with a history of polyarticular gout attacks
whereas disabling foot pain was associated with ischaemic
heart disease. Foot problems were a common reason to
consult a health professional, with almost one-half seeing
their GP in the last 12 months and nearly one-quarter a
podiatrist/chiropodist.
There are few previous studies of foot problems in
people with gout in primary care. A small primary-care
based study found a similar prevalence of hallux valgus
of 41 % [4]. The prevalence of chronic big toe pain was
16 % which is consistent with our finding that of the
22 % who reported foot pain in the preceding month,
the 1st MTPJ (72 %) and hallux (59 %) were commonly
affected. It is noteworthy, however, that the lesser toes,
mid-foot, ankle, plantar heel and posterior heel were also
commonly painful. In this previous study [4], both hallux
valgus and big toe pain were more than twice as com-
mon in people with gout as matched gout-free control
subjects. Our current findings did not find evidence to
support a role for gout-specific or comorbid factors in
the increased prevalence of hallux valgus in gout. There
are various risk factors described for hallux valgus which
were not assessed in our study, for example footwear,
foot posture and 1st MTPJ OA [6–8]. Similarly foot pain
in the general population has been shown to associate
with obesity and footwear [9–11]. Whilst footwear worn
by people with gout is frequently suboptimal [16] and
gout occurs more frequently at osteoarthritic 1st MTPJs
[29, 30], little is known about foot posture in gout. The
Table 2 Demographic, lifestyle, psychological, co-morbid and
gout characteristics of survey responders (n = 1184)
n (%)
Marital status:
Married/Co-habiting 882 (75.7)
Divorced/separated 91 (7.8)
Widowed 114 (9.8)
Single 78 (6.7)
Higher education:
Yes 249 (22.3)
No 870 (77.8)
Employment status:
Employed 401 (34.9)
Retired 656 (57.1)
Not working 35 (3.1)
Othera 56 (4.9)
Ethnicity:
White 1126 (97.6)
Non-white 28 (2.4)
BMI (kg/m2):
<25.0 221 (19.8)
25.0–29.9 511 (45.7)
30.0–34.9 260 (23.2)
≥35.0 127 (11.4)
Anxiety:
None 844 (77.2)
Mild 141 (12.9)
Moderate 64 (5.9)
Severe 45 (4.1)
Depression:
None 763 (73.2)
Mild 148 (14.2)
Moderate 65 (6.2)
Moderately severe 40 (3.8)
Severe 26 (2.5)
Co-morbid conditions:
Diabetes mellitus 205 (17.3)
Hypertension 731 (61.7)
Hyperlipidaemia 508 (42.9)
Ischaemic heart disease 215 (18.2)
Cerebrovascular disease 86 (7.3)
Alcohol consumption:
Daily/almost daily 273 (23.4)
3–4 times per week 263 (22.5)
1–2 times per week 254 (21.8)
1–3 times per month 109 (9.3)
Table 2 Demographic, lifestyle, psychological, co-morbid and
gout characteristics of survey responders (n = 1184) (Continued)
Occasionally 155 (13.3)
Never 113 (9.7)
Gout characteristics:
Duration, years (mean, (SD)) 11.9 (12.1)
Current attack 132 (11.6)
Number of attacks in last 12 months:
0 398 (35.4)
1–2 418 (37.2)
≥3 307 (27.3)
Oligo/polyarticular attacks 436 (38.6)
Current allopurinol use 630 (56.3)
Tophi 25 (2.3)b
Highest SUA (mean (SD), μmol/l) 441 (116)b,c
BMI body mass index, SD standard deviation, SUA serum uric acid
aIncludes those who are off work sick for less than 6 months, in education,
looking after the home/children
bIn those with permission to access medical records (n = 1079)
cin 461 people with one or more measurement of uric acid recorded
Roddy et al. Journal of Foot and Ankle Research  (2015) 8:31 Page 6 of 11
Table 3 Factors associated with hallux valgus
Hallux valgus n(%) No hallux valgus n(%) Unadjusted OR (95 % CI) Adjusted ORa (95 % CI)
N 418 714 - -
Age, mean (SD) 68.7 (11.8) 63.6 (12.6) 1.41b (1.27, 1.57) 1.47b (1.26, 1.72)
Gender:
Male 313 (74.9) 636 (89.1) 1.0 1.0
Female 105 (25.1) 78 (10.9) 2.74 (1.98, 3.78) 2.03 (1.31, 3.15)
Neighbourhood deprivation tertiles:
Most deprived 131 (31.3) 219 (30.7) 1.0 1.0
Mid-deprived 148 (35.4) 236 (33.1) 1.05 (0.78, 1.41) 0.97 (0.67, 1.40)
Least deprived 139 (33.3) 259 (36.3) 0.90 (0.67, 1.21) 1.02 (0.70, 1.48)
BMI (kg/m2):
<25.0 83 (21.5) 132 (19.2) 1.0 1.0
25.0–29.9 171 (44.2) 315 (45.9) 0.86 (0.62, 1.20) 1.04 (0.70, 1.56)
30.0–34.9 88 (22.7) 162 (23.6) 0.86 (0.59, 1.26) 1.29 (0.81, 2.05)
≥35.0 45 (11.6) 77 (11.2) 0.93 (0.59, 1.47) 1.21 (0.68, 2.16)
Anxiety:
None 287 (74.0) 534 (79.4) 1 1
Mild 52 (13.4) 82 (12.2) 1.18 (0.81, 1.72) 1.04 (0.61, 1.77)
Moderate 29 (7.5) 32 (4.8) 1.69 (1.00 2.84) 1.37 (0.60, 3.10)
Severe 20 (5.2) 25 (3.7) 1.49 (0.81, 2.73) 0.83 (0.31, 2.25)
Depression:
None 249 (68.0) 489 (76.4) 1 1
Mild 62 (16.9) 82 (12.8) 1.48 (1.03, 2.14) 1.36 (0.85, 2.19)
Moderate 23 (6.3) 38 (5.9) 1.19 (0.69, 2.04) 1.33 (0.62, 2.87)
Moderately severe 20 (5.5) 18 (2.8) 2.18 (1.13, 4.20) 1.39 (0.52, 3.72)
Severe 12 (3.3) 13 (2.0) 1.81 (0.82, 4.03) 1.83 (0.53, 6.37)
Comorbidity:
Diabetes mellitus 73 (17.5) 119 (16.7) 1.06 (0.77, 1.46) 0.69 (0.46, 1.06)
Hypertension 279 (66.8) 420 (58.8) 1.41 (1.09, 1.81) 0.83 (0.58, 1.17)
Hyperlipidaemia 192 (45.9) 299 (41.9) 1.18 (0.92, 1.50) 1.18 (0.85, 1.62)
Ischaemic heart disease 86 (20.6) 121 (17.0) 1.26 (0.93, 1.73) 0.89 (0.59, 1.33)
Cerebrovascular disease 35 (8.4) 46 (6.4) 1.33 (0.84, 2.10) 1.14 (0.70, 2.18)
Gout characteristics:
Duration, mean (SD) 12.7 (12.9) 11.4 (11.6) 1.09c (0.98, 1.21) 1.14c (0.99, 1.31)
Current attack 54 (13.6) 72 (10.4) 1.34 (0.93, 1.97) 1.07 (0.63, 1.82)
Number of attacks in last 12 months:
0 136 (34.3) 244 (35.8) 1.0 1.0
1–2 152 (38.1) 251 (36.8) 1.08 (0.81, 1.44) 1.06 (0.73, 1.54)
≥3 109 (27.5) 187 (27.4) 1.05 (0.76, 1.43) 1.12 (0.72, 1.75)
Oligo/polyarticular attacks 159 (39.9) 261 (38.0) 1.08 (0.84, 1.39) 0.96 (0.69, 1.33)
Current allopurinol use 222 (56.5) 379 (55.7) 1.03 (0.80, 1.32) 1.06 (0.75, 1.49)
BMI body mass index, CI confidence interval, OR odds ratio, SD standard deviation
aOR adjusted for age, gender, deprivation, BMI, anxiety, depression, comorbidity and gout characteristics
bper 10-year increase in age
cper 10-year increase in duration of disease
Roddy et al. Journal of Foot and Ankle Research  (2015) 8:31 Page 7 of 11
Table 4 Factors associated with foot pain in the last month
Foot pain in last month
n (%)
No foot pain in last month
n (%)
Unadjusted OR
(95 % CI)
Adjusteda OR
(95 % CI)
N 248 875 - -
Age, mean (SD) 66.6 (11.7) 65.0 (12.7) 1.11b (0.99, 1.24) 1.14b (0.94, 1.38)
Gender:
Male 190 (76.6) 752 (85.9) 1.0 1.0
Female 58 (23.4) 123 (14.1) 1.87 (1.31, 2.65) 1.33 (0.77, 2.30)
Neighbourhood deprivation tertiles:
Most deprived 93 (37.5) 258 (29.5) 1.0 1.0
Mid-deprived 78 (31.5) 304 (34.7) 0.71 (0.50, 1.00) 0.81 (0.50, 1.31)
Least deprived 77 (31.1) 313 (35.8) 0.68 (0.48, 0.96) 1.14 (0.71, 1.82)
BMI (kg/m2):
<25.0 34 (15.2) 177 (21.1) 1.0 1.0
25.0–29.9 90 (40.2) 397 (47.2) 1.18 (0.77, 1.82) 1.64 (0.89, 2.99)
30.0–34.9 62 (27.7) 182 (21.6) 1.77 (1.11, 2.83) 2.23 (1.16, 4.27)
≥35.0 38 (17.0) 85 (10.1) 2.33 (1.37, 3.95) 2.61 (1.25, 5.45)
Anxiety:
None 133 (60.7) 677 (81.8) 1.0 1.0
Mild 41 (18.7) 96 (11.6) 2.17 (1.44, 3.28) 1.05 (0.57, 1.95)
Moderate 25 (11.4) 34 (4.1) 3.74 (2.16, 6.48) 1.38 (0.56, 3.39)
Severe 20 (9.1) 21 (2.5) 4.85 (2.56, 9.19) 1.21 (0.41, 3.51)
Depression:
None 93 (47.0) 644 (80.2) 1.0 1.0
Mild 52 (26.3) 90 (11.2) 4.00 (2.67, 6.00) 3.02 (1.78, 5.11)
Moderate 20 (10.1) 43 (5.4) 3.22 (1.82, 5.71) 1.42 (0.58, 3.46)
Moderately severe 20 (10.1) 18 (2.2) 7.69 (3.93, 15.08) 3.41 (1.22, 9.57)
Severe 13 (6.6) 8 (1.0) 11.25 (4.54, 27.88) 4.55 (1.20, 17.18)
Comorbidity:
Diabetes mellitus 59 (23.8) 134 (15.3) 1.73 (1.22, 2.44) 1.00 (0.60, 1.66)
Hypertension 166 (66.9) 529 (60.5) 1.32 (0.98, 1.78) 0.98 (0.62, 1.57)
Hyperlipidaemia 117 (47.2) 374 (42.7) 1.20 (0.90, 1.59) 1.12 (0.74, 1.71)
Ischaemic heart disease 56 (22.6) 140 (16.0) 1.53 (1.08, 2.17) 1.43 (0.87, 2.35)
Cerebrovascular disease 18 (7.3) 62 (7.1) 1.03 (0.60, 1.77) 0.83 (0.40, 1.69)
Gout characteristics:
Duration, mean (SD) 12.7 (13.4) 11.8 (11.8) 1.06c (0.94, 1.20) 1.05c (0.88, 1.25)
Current attack 62 (26.1) 65 (7.7) 4.21 (2.87, 6.19) 2.38 (1.35, 4.20)
Number of attacks in last 12 months:
0 63 (27.2) 313 (37.5) 1.0 1.0
1–2 77 (33.2) 323 (38.7) 1.18 (0.82, 1.71) 0.96 (0.58, 1.59)
≥3 92 (39.7) 199 (23.8) 2.30 (1.59, 3.31) 1.17 (0.66, 2.05)
Oligo/polyarticular attacks 132 (56.4) 289 (34.4) 2.47 (1.84, 3.32) 1.67 (1.11, 2.51)
Current allopurinol use 144 (62.1) 463 (55.6) 1.31 (0.97, 1.76) 1.11 (0.72, 1.72)
BMI body mass index, CI confidence interval, OR odds ratio, SD standard deviation
aOR adjusted for age, gender, deprivation, BMI, anxiety, depression, comorbidity and gout characteristics
bper 10-year increase in age
cper 10-year increase in duration of disease
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Table 5 Factors associated with disabling foot pain
Disabling foot pain
in last month n(%)
No disabling foot pain
in last montha n(%)
Unadjusted OR
(95 % CI)
Adjustedb OR
(95 % CI)
N 155 923
Age, mean (SD) 66.3 (11.9) 64.8 (12.6) 1.11c (0.96, 1.27) 1.24c (0.98, 1.56)
Gender:
Male 120 (77.4) 796 (86.2) 1.0 1.0
Female 35 (22.6) 127 (13.8) 1.83 (1.20, 2.78) 1.59 (0.85, 2.95)
Neighbourhood deprivation tertiles:
Most deprived 64 (41.3) 273 (29.6) 1.0 1.0
Mid-deprived 46 (29.7) 316 (34.2) 0.62 (0.41, 0.94) 0.83 (0.47, 1.46)
Least deprived 45 (29.0) 334 (36.2) 0.57 (0.38, 0.87) 0.96 (0.55, 1.68)
BMI (kg/m2):
<25.0 19 (13.4) 185 (20.9) 1.0 1.0
25.0–29.9 54 (38.0) 418 (47.1) 1.26 (0.73, 2.18) 1.73 (0.82, 3.64)
30.0–34.9 41 (28.9) 195 (22.0) 2.05 (1.15, 3.66) 2.44 (1.10, 5.41)
≥35.0 28 (19.7) 89 (10.0) 3.06 (1.62, 5.78) 3.10 (1.28, 7.47)
Anxiety:
None 83 (55.3) 714 (81.7) 1.0 1.0
Mild 31 (20.7) 101 (11.6) 2.64 (1.66, 4.19) 1.13 (0.56, 2.28)
Moderate 20 (13.3) 37 (4.2) 4.65 (2.58, 8.38) 1.53 (0.56, 4.20)
Severe 16 (10.7) 22 (2.5) 6.26 (3.16, 12.39) 1.05 (0.31, 3.55)
Depression:
None 55 (39.6) 675 (79.8) 1.0 1.0
Mild 39 (28.1) 99 (11.7) 4.83 (3.05, 7.67) 3.27 (1.80, 5.97)
Moderate 16 (11.5) 45 (5.3) 4.36 (2.32, 8.22) 2.45 (0.92, 6.51)
Moderately severe 16 (11.5) 19 (2.3) 10.33 (5.03, 21.22) 4.16 (1.28, 13.51)
Severe 13 (9.4) 8 (1.0) 19.94 (7.93, 50.17) 8.81 (2.04, 38.01)
Comorbidity:
Diabetes mellitus 41 (26.5) 141 (15.3) 1.99 (1.34, 2.97) 0.90 (0.50, 1.62)
Hypertension 106 (68.4) 561 (60.8) 1.40 (0.97, 2.01) 0.81 (0.46, 1.42)
Hyperlipidaemia 86 (55.5) 392 (42.5) 1.69 (1.20, 2.38) 1.38 (0.83, 2.29)
Ischaemic heart disease 45 (29.0) 145 (15.7) 2.19 (1.49, 3.24) 1.84 (1.06, 3.20)
Cerebrovascular disease 9 (5.8) 66 (7.2) 0.80 (0.39, 1.64) 0.67 (0.29, 1.57)
Gout characteristics:
Duration (mean (SD)) 13.5 (13.9) 11.7 (11.7) 1.12d (0.98, 1.29) 1.17d (0.96, 1.42)
Current attack 48 (32.2) 72 (8.1) 5.39 (3.54, 8.19) 2.63 (1.39, 4.98)
Number of attacks in last 12 months:
0 39 (26.4) 328 (37.3) 1.00 1.00
1–2 44 (29.7) 341 (38.8) 1.09 (0.69, 1.71) 0.94 (0.51, 1.73)
≥3 65 (43.9) 211 (24.0) 2.59 (1.59, 3.99) 1.26 (0.64, 2.47)
Oligo/polyarticular attacks 87 (58.8) 310 (35.0) 2.65 (1.86, 3.78) 1.59 (0.98, 2.58)
Current allopurinol use 91 (62.3) 490 (55.8) 1.31 (0.91, 1.88) 1.13 (0.67, 1.90)
BMI body mass index, CI confidence interval, OR odds ratio, SD standard deviation
ano foot pain or foot pain that is not disabling
bOR adjusted for age, gender, deprivation, BMI, anxiety, depression, comorbidity and gout characteristics
cper 10-year increase in age
dper 10-year increase in duration of disease
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specific association observed between disabling foot pain
and ischaemic heart disease is an interesting finding.
The explanation for this observation is not clear but it is
possible that disabling foot pain arises from other condi-
tions associated with ischaemic heart disease that we did
not assess (for example, peripheral vascular disease) or is
a marker of general frailty.
The frequency of consultation with a healthcare pro-
fessional for foot problems was higher in people with
gout in this study than that previously observed in
people with foot problems in the general population
(not specific to gout). In our study, 43 % of people with
gout consulted their GP about foot problems in the pre-
ceding 12 months compared with 12 % of people with
foot problems over 18 months in the general population
[17]. Similarly, 24 % of people with gout consulted a po-
diatrist over 12 months compared to 18 % in the general
population [18]. It is to be expected that the consult-
ation prevalence should be lower for podiatrists than
GPs, since consultation with a podiatrist in the UK
generally requires a referral from a GP. These findings
suggest that foot problems in people with gout may be
more severe than in the general population emphasising
the need to provide specific assessment and treatment of
foot problems in people with gout.
This is the largest study of foot problems in people
with gout to date. Further strengths include the primary
care setting, ensuring relevance to the majority of pa-
tients with gout who are managed entirely in primary
care, and the use of weighted logistic regression to ac-
count for non-response. Limitations of our study include
the reliance on a primary care diagnosis of gout [31] al-
though our previous work has shown this to be reasonably
accurate [32, 33]. Response to the postal questionnaire
was acceptable although responders were older, more
likely to be male and were less socioeconomically de-
prived. This was partially addressed by inverse probability
weighting based on these variables. The external validity
of our findings is reduced by the low representation of
ethnic minority groups which is typical of the source
population [34]. The study assessed hallux valgus using a
validated line-drawing instrument [20] which was in-
cluded in the postal questionnaire. Ascertainment of hal-
lux valgus via self-report, rather than clinical assessment,
risks under-estimating its prevalence [35]. Other 1st MTPJ
deformities such as hallux rigidus might also be relevant
to people with gout but could not be assessed in a postal
self-report questionnaire. A further limitation is that the
underlying cause of foot pain is not known but possible
causes include attacks of acute gout, chronic erosive ar-
thropathy, co-existent OA, pain related to comorbidity
(for example peripheral vascular disease), or soft tissue
pathology. The possibility that foot pain in gout could re-
late to comorbid conditions or arise from soft tissue
structures is supported by our findings that disabling foot
pain was associated with ischaemic heart disease and that
pain in the plantar heel and posterior heel was prevalent.
Our findings suggest that patients with gout should
undergo comprehensive clinical assessment of their feet
and be offered specific multidisciplinary treatment for foot
problems, such as gout-specific foot education and pro-
motion, foot orthoses and good footwear [36, 37]. The
association of foot pain with gout characteristics (history
of oligo/polyarticular attacks) provides justification for
ensuring optimal use of urate-lowering therapy to achieve
target serum urate levels. Further research is needed to
ascertain the causes of disabling chronic foot pain in gout,
via clinical assessment, and to develop evidence-based
treatments for foot problems in people with gout.
Conclusions
Foot problems are common findings in people with gout
and frequently lead to consultation with healthcare pro-
fessionals. One-third of people with gout have hallux
valgus and approximately one-quarter report experien-
cing foot pain in the last month. Nearly two-thirds of
those with foot pain report disabling symptoms. Hallux
valgus associated with age and gender, similar to the
general population, whereas foot pain associates with
obesity and gout characteristics, and disabling foot pain
with obesity and comorbidity. These findings suggest
that foot problems present significant difficulties to
people with gout who need evidence-based, multidiscip-
linary foot-specific interventions.
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